National prevalence and trends of hiv transmitted drug resistance in mexico

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Avila Ríos, Santiago ^a   García Morales, Claudia ^a   Garrido Rodríguez, Daniela ^a   Ormsby, Christopher E ^a   Hernández Juan, Ramón ^a   Andrade Villanueva, Jaime ^b,c   González Hernández, Luz A ^b,c   Torres Escobar, Indiana ^d,e   Navarro Álvarez, Samuel ^f   Reyes Terán, Gustavo ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

^d Hospital General de Puebla   (Mexico)

^e BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^f Hospital General de Tijuana   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA DIRECTED RNA POLYMERASE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG RESISTANCE; FEMALE; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MEXICO; MICROBIAL DIVERSITY; MOLECULAR EPIDEMIOLOGY; PREVALENCE; PROSPECTIVE STUDY; SCORING SYSTEM; STRUCTURAL GENE; TRANSMITTED DRUG RESISTANCE; TREND STUDY; ANTIVIRAL RESISTANCE; BLOOD; CLASSIFICATION; DRUG EFFECT; ENZYMOLOGY; EPIDEMIC; GENETIC VARIABILITY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYLOGENY; STATISTICS;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, VIRAL; EPIDEMICS; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEXICO; PHYLOGENY; PREVALENCE;

EID: 84858771311     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027812     Document Type: Article

References (41)

1. (2007) Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. Aids 21: 1035-1039.
2. Booth CL, Geretti AM, (2007) Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J Antimicrob Chemother 59: 1047-1056.
3. Callegaro A, Svicher V, Alteri C, Lo Presti A, Valenti D, et al. (2011) Epidemiological network analysis in HIV-1 B infected patients diagnosed in Italy between 2000 and 2008. Infect Genet Evol [Epub ahead of print].
4. Cardoso LP, Queiroz BB, Stefani MM, (2009) HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naive patients from Central West Brazil. J Clin Virol 46: 134-139.
5. Geretti AM, (2007) Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 20: 22-32.
6. Hattori J, Shiino T, Gatanaga H, Yoshida S, Watanabe D, et al. (2010) Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 88: 72-79.
7. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, et al. (2010) Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. Aids 24: 1203-1212.
8. Jayaraman GC, Archibald CP, Kim J, Rekart ML, Singh AE, et al. (2006) A population-based approach to determine the prevalence of transmitted drug-resistant HIV among recent versus established HIV infections: results from the Canadian HIV strain and drug resistance surveillance program. J Acquir Immune Defic Syndr 42: 86-90.
9. Wong KH, Chan WK, Yam WC, Chen JH, Alvarez-Bognar FR, et al. (2010) Stable and low prevalence of transmitted HIV type 1 drug resistance despite two decades of antiretroviral therapy in Hong Kong. AIDS Res Hum Retroviruses 26: 1079-1085.
10. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis [Epub ahead of print].
11. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF, (2008) The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 13 (Suppl 2): 1-13.
12. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB, (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000.
13. Payne BA, Nsutebu EF, Hunter ER, Olarinde O, Collini P, et al. (2008) Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort. J Antimicrob Chemother 62: 464-468.
14. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, et al. (2009) Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 200: 1503-1508.
15. Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT, (2008) The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr 49: 196-204.
16. Shafer RW, Rhee SY, Bennett DE, (2008) Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies. Antivir Ther 13 (Suppl 2): 59-68.
17. Shafer RW, Schapiro JM, (2008) HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67-84.
18. CENSIDA (2009) El VIH/SIDA en México 2009. http://www.censida.salud.gob.mx/descargas/2009/VIHSIDAenMexico2009.pdf.
19. Bautista-Arredondo S, Dmytraczenko T, Kombe G, Bertozzi SM, (2008) Costing of scaling up HIV/AIDS treatment in Mexico. Salud Publica Mex 50 (Suppl 4): S437-444.
20. Geretti AM, (2006) HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19: 1-7.
21. Hemelaar J, Gouws E, Ghys PD, Osmanov S, (2006) Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. Aids 20: W13-23.
22. LANL (2010) Los Alamos HIV Database. HIV sequence database. Geography Search Interface.
23. UNAIDS (2010) UNAIDS Report on the Global AIDS Epidemic 2010. http://www.unaids.org/globalreport/Global_report.htm.
24. Vazquez-Valls E, Escoto-Delgadillo M, Lopez-Marquez FC, Castillero-Manzano M, Echegaray-Guerrero E, et al. (2010) Molecular epidemiology of HIV type 1 in Mexico: emergence of BG and BF intersubtype recombinants. AIDS Res Hum Retroviruses 26: 777-781.
25. Eyzaguirre L, Brouwer KC, Nadai Y, Patterson TL, Ramos R, et al. (2007) First molecular surveillance report of HIV type 1 in injecting drug users and female sex workers along the U.S.-Mexico border. AIDS Res Hum Retroviruses 23: 331-334.
26. Rivera-Morales LG, Novitsky VA, Trujillo JR, Lavalle-Montalvo C, Cano-Dominguez C, et al. (2001) The molecular epidemiology of HIV type 1 of men in Mexico. AIDS Res Hum Retroviruses 17: 87-92.
27. Pyne MT, Holzmayer V, Hackett J, Hillyard DR., Analysis of HIV subtype prevalence and geographic distribution in a large U. S. population; 2009; Montreal, Canada.
28. CENSIDA (2010) Panorama Epidemiológico del VIH/SIDA en México. Casos al 15 de Noviembre del 2010. http://www.censida.salud.gob.mx/interior/panorama.html.
29. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
30. Stanford-University (2006) Stanford HIV Drug Resistance Database. HIVdb Program. http://sierra2.stanford.edu/sierra/servlet/JSierra.
31. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724.
32. Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, et al. (2008) World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 13 (Suppl 2): 49-57.
33. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
34. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, et al. (2005) An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 21: 3797-3800.
35. Bioafrica (2006) REGA HIV-1 & 2 Automated Subtyping Tool (Version 2.0) http://www.bioafrica.net/subtypetool/html/subtypinghiv.html.
36. LANL (2011) Los Alamos HIV Database. RIP HIV Recombinant Identification Program. http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html.
37. Paradis E, Claude J, Strimmer K, (2004) APE: Analyses of Phylogenetics and Evolution in R language. Bioinformatics 20: 289-290.
38. Stanford-University (2006) HIV Drug Resistance Database. http://hivdb.stanford.edu/.
39. Calva-Mercado J, Vargas-Infante Y, (2009) Cobertura universal con la terapia antirretroviral combinada. Logros y desafíos en la Secretaría de Salud de México. In: Córdova-Villalobos J, Ponce de León-Rosales S, Valdespino J, editors. 25 años de SIDA en México Logros, Desaciertos y Retos. 2nd Edition Mexico City INSP pp. 333-354.
40. Magis-Rodriguez C, Lemp G, Hernandez MT, Sanchez MA, Estrada F, et al. (2009) Going North: Mexican migrants and their vulnerability to HIV. J Acquir Immune Defic Syndr 51 (Suppl 1): S21-25.
41. CENSIDA (2010) Boletín SALVAR. http://www.censida.salud.gob.mx/interior/atencion/bol_salvar.html.